Plasma levels of α1-antitrypsin-derived C-terminal peptides in PiMM and PiZZ COPD patients

Friedemann R Börner; Urszula Lechowicz; Sabine Wrenger; Beatriz Martinez-Delgado; Beata Olejnicka; Tobias Welte; Joanna Chorostowska-Wynimko; Michael Kiehntopf; Sabina Janciauskiene

doi:10.1183/23120541.00329-2023

Plasma levels of α₁-antitrypsin-derived C-terminal peptides in PiMM and PiZZ COPD patients

ERJ Open Res. 2023 Dec 4;9(6):00329-2023. doi: 10.1183/23120541.00329-2023. eCollection 2023 Nov.

Authors

Affiliations

¹ Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany.
² Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases Warsaw, Poland, Poland.
³ Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Biomedical Research in Endstage and Obstructive Lung Disease Hannover BREATH, German Center for Lung Research DZL, Hannover, Germany.
⁴ Molecular Genetics Unit, Institute of Rare Diseases Research (IIER), CIBER of Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain.
⁵ These authors contributed equally and share last authorship.

Abstract

Plasma levels of α₁-antitrypsin-derived C-terminal peptides might be valid as novel biomarkers to predict and/or characterise exacerbations in PiMM and PiZZ COPD patients, or to reflect the efficiency of augmentation therapy in PiZZ patients https://bit.ly/3rNJeLd.